Roivant's Newest Company to Develop Ligand's Diabetes Candidate LGD-6972

Roivant Sciences will partner with Ligand Pharmaceuticals to codevelop its type 2 diabetes candidate LGD-6972 through a collaboration that could generate up to $533.8 million for Ligand—and is aimed at developing the second pipeline candidate of Roivant’s new and seventh biotech spinout, focused on cardiometabolic drugs.LGD-6972—which Roivant plans to rename RVT-1502—is an oral, small-molecule glucagon receptor antagonist (GRA) that last year generated positive Phase II r